Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 233 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
Patents for C07D 233 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings (34,408)
10/2004
10/27/2004CN1541063A Method for controlling particular insects by applying anthranilamide compounds
10/27/2004CN1539826A Precursor of Lisinopril compound and synthetic method
10/27/2004CN1539820A Aza aromatic ring substitutional four branched functional molecule material and preparation method
10/27/2004CN1172892C Stabilised compositions of 0-and N-vinyl compounds and the use of ammonium salts as stabilisers
10/26/2004US6809205 1,3-dibromomination of 5,5-dimethylhydantoin; forming pale yellow to white material
10/26/2004US6809202 Diketodiazacyclic compounds, diazacyclic compounds and combinatorial libraries thereof
10/26/2004US6809088 Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
10/26/2004CA2196263C Process for the preparation of 4-oxoimidazolinium salts
10/21/2004WO2004089941A1 New heterocyclic compounds, a process for their preparation and their use as dyes and pigments
10/21/2004WO2004089937A1 7-membered heterocyclic derivative
10/21/2004WO2004089927A1 Novel methods for the treatment of inflammatory diseases
10/21/2004WO2004089885A1 Novel compounds
10/21/2004WO2004089881A1 New sulfonyl derivatives of aminonaphtols
10/21/2004WO2004089877A1 New hydroxynaphthyl amides
10/21/2004WO2004089313A2 Novel olanzapine forms and related methods of treatment
10/21/2004US20040210064 Production method of beta-amino acid
10/21/2004US20040210060 Process for the separation of enantiomers and enantiopure reagent
10/21/2004US20040210051 Inhibitors of binding between vascular cell adhesion molecules and cells expressing vla-4 integrin; antiinflammatory agents
10/21/2004US20040209939 Pyrrole derivatives
10/21/2004US20040209928 saturated 5-member heterocyclyl-substituted (hetero)aroylaminoalkyl compounds, e.g., N-(4-{3-(4-tert-butylcyclohexyl)-2-oxo-1-[4-(trifluoromethoxy)phenyl]imidazolidin-4-yl}benzoyl)-beta-alanine and N-(4-{3-(4-tert-butylphenyl)-2-oxo-1-[4-(trifluoromethoxy)phenyl]imidazolidin-4-yl}benzoyl)-beta-alanine.
10/21/2004US20040209926 asymmetrically-substituted xylylenediamines, e.g., N-(3-aminopropyl)-xylylenediamine; cancer, mucositis, asthma, inflammation, autoimmune disease, psoriasis, restentosis, rheumatoid arthritis, scleroderma, lupus, diabetes, tissue transplantation, osteoporosis, hyperparathyroidism, peptic ulcers, glaucoma
10/21/2004US20040209908 New derivatives of hydantoins, thiohydantoins, pyrimidinediones and thioxopyrimidinones, their preparation processes and their use as medicaments
10/21/2004US20040209874 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
10/21/2004US20040209863 5-chloro-N-(5-chloropyridin-2-yl)-2-[(4-{(Z)-(dimethylamino)[(methylsulfonyl)imino]methyl}benzoyl)amino]benzamide; treating thromboembolic disorders, optionally with other active agents
10/21/2004US20040208808 Solvent extraction mixture comprising substituted imidazole or benzimidazole for the purification of groups of base metals
10/21/2004US20040205909 Novel couplers for use in oxidative hair dyeing
10/21/2004US20040205907 Making 2-amino-5-substituted-amino-phenol derivatives by reduction, hydrogenation, amination, hydroxylation; oxidation color dyes, hair dye mixture including coupler and developer oxidizers, yellow color shades, colorfastness
10/21/2004CA2521606A1 Novel methods for the treatment of inflammatory diseases
10/21/2004CA2519157A1 New heterocyclic compounds, a process for their preparation and their use as dyes and pigments
10/20/2004EP1469012A1 Polymerisation initiator system
10/20/2004EP1468990A1 Piperazine derivative
10/20/2004EP1468002A2 Coordination complex
10/20/2004EP1467989A1 Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatitis c virus infection
10/20/2004EP1467973A1 Onium salts with weakly coordinating imidazolidine anion as cationic initiators
10/20/2004EP1467744A2 Aqueous compositions containing metronidazole
10/20/2004EP1467731A1 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
10/20/2004EP1443045A9 Carbanilide used as pesticide
10/20/2004EP1261588B1 IMIDAZOLE COMPOUNDS AS Alpha2-ADRENOCEPTORS ANTAGONISTS
10/20/2004EP0862555B1 Substituted aryl or heteroarylamides having retinoid-like biological activity
10/20/2004CN1538951A Omega-aminoalkylamides of R-2-aryl-propionic acids as inhibitors of chemotaxis of polymorphonucleate and mononucleate cells
10/20/2004CN1171874C Combinations of protein farnesyltransferase and HMG COA reductase inhibitors and their use to treat cancer
10/19/2004US6806369 N-formyl-n-hydroxy-2-(5-isoquinolinoxy)ethylamine anti-bacterial compounds
10/19/2004US6806365 N-alkanoylphenylalamine derivatives
10/19/2004CA2117034C Process for the production of 2-substituted-5-chlorimidazole-4-carbaldehydes
10/14/2004WO2004087653A2 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5
10/14/2004WO2004087641A1 Hydrazone derivative
10/14/2004WO2004087075A2 Compositions and methods for treating cancer
10/14/2004WO2004087066A2 Hif-1 inhibitors
10/14/2004WO2004087061A2 Tubulin binding agents and corresponding prodrug constructs
10/14/2004WO2004071448A3 Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
10/14/2004WO2004056727A3 Process of making chalcone derivatives
10/14/2004WO2004050636A3 IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
10/14/2004WO2004004655A3 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
10/14/2004US20040204599 an end-terminal group, which is isopropyl, sec.-butyl, or tert.-butyl group; a leading group; and a long-chain aliphatic, non-cyclic, saturated or unsaturated, hydrocarbon group that links end-terminal group and leading group; for cancer therapy, prevention, and immune boosting and inflammation functions
10/14/2004US20040204583 Aminophenoxyethyl quaternary ammonium halides or sulfates, e.g., (2-(3-dimethylaminophenoxy)ethyl)trimethylammonium bromide
10/14/2004US20040204502 Such as 4-(4-(3-hydroxy-3-methyl-butane-1-sulfinylmethyl)-phenylmethanesulfinyl)-2 -methyl-butan1-ol for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders
10/14/2004US20040204436 Imidazonaphthyridines
10/14/2004US20040204412 Useful as anticoagulants in therapy and prophylaxis of cardiovascular diseases, as anti-inflammatory agents, and as metastasis inhibitors in therapy of cancer
10/14/2004US20040204410 Such as 1-(4,5-Bis-(4-chloro-phenyl)-2-(2,4-dimethoxy-phenyl)-4,5-dihydro-imidazol-1-yl)-2-methyl-propan-1-one which inhibits the interaction of MDM2 protein with p53-like peptide; antiproliferative agents
10/14/2004US20040204390 Pharmaceutical combination comprising an anti-androgen and an oestrogen receptor beta agonist
10/14/2004US20040200996 such as N-propyl-2-heptadecenyl imidazoline acrylate; for low carbon steel lines
10/14/2004CA2522441A1 Hif-1 inhibitors
10/14/2004CA2521056A1 Hydrazone derivative
10/14/2004CA2520863A1 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5
10/13/2004EP1466898A1 Beta-amyloid protein production/secretion inhibitors
10/13/2004EP1466888A1 Calcium receptor-active arylalkyl amines
10/13/2004EP1466602A1 Organ fibrosis inhibitors
10/13/2004EP1465891A2 Inhibitors of dipeptidyl peptidase iv
10/13/2004EP1465863A1 Potassium channel modulators
10/13/2004EP1465862A1 Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors
10/13/2004EP1465861A1 Alpha-(n-sulphonamido)acetamide derivatives as beta-amyloid inhibitors
10/13/2004EP1465854A2 Chalcone derivatives and their use to treat diseases
10/13/2004EP1465630A1 Cyclic urea derivatives with 5-ht2c receptor activity
10/13/2004EP1465599A1 Liposome composition for delivery of nucleic acid
10/13/2004EP1465490A2 Nematicidal trifluorobutenyl imidazole thioether derivatives
10/13/2004EP1397137A4 Hydantion derivatives as inhibitors of matrix metalloproteinases
10/13/2004EP1322309A4 High affinity small molecule c5a receptor modulators
10/13/2004EP1169038A4 Cyclic protein tyrosine kinase inhibitors
10/13/2004EP1086086B1 Imidazolyl derivatives and their use as somatostatin receptor ligands
10/13/2004CN1537001A Malonyl-COA decarboxylase inhibitors useful as metabolic modulators
10/13/2004CN1537000A Novel imidazolidine derivatives, their preparation and their use as VLA-4 antagonists
10/13/2004CN1170826C Amide compounds
10/13/2004CN1170822C Imidazole compounds and medicinal use thereof
10/13/2004CN1170821C Preparation of naphthenic acid
10/12/2004US6803429 Selective ring-opening cross-metathesis of cycloolefins
10/12/2004US6803367 Substance for inducing apoptosis
10/07/2004WO2004085428A1 A new process for preparing olmesartan medoxomil
10/07/2004WO2004085421A2 Bioreductively-activated prodrugs
10/07/2004WO2004085388A2 Cyclic protein tyrosine kinase inhibitors
10/07/2004WO2004084890A1 Therapeutic and prophylactic compositions and uses therefor
10/07/2004WO2004084843A2 Inhibitors of cathepsin s
10/07/2004WO2004060987A3 Catalytic depolymerization of polymers containing electrophilic linkages using nucleophilic reagents
10/07/2004WO2004012659A3 Nitrosated proton pump inhibitors, compositions and methods of use
10/07/2004WO2004010949A3 Compounds active in spinigosine 1-phosphate signaling
10/07/2004US20040198986 Chemical compounds
10/07/2004US20040198982 such as (4S)-1-(3-bromophenyl)-N-cyanomethyl)-4-methyl-prolinamide; for treatment of osteoporosis
10/07/2004US20040198814 prevention , therapy of cardiovascular disorders, dyslipidemias, glucose metabolism, hypoglycemic agents; reduce fat concentration in meat; reduce cholesterol concentration in eggs
10/07/2004US20040198796 Compounds and methods for treating urinary incontinence
10/07/2004US20040198795 Substituted imidazoliums and methods of use therefor
10/07/2004US20040198792 Imidazole derivatives modulating the sodium channels
1 ... 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 ... 345